Teleflex (TFX) 2026 stock analysis: recurring single-use device revenue across catheters, vascular access, and UroLift, the planned separation of Urology, Acute Care and OEM, the BIOTRONIK vascular deal, UroLift's growth debate, and margins funding deleveraging.
A practical 2026 guide to medical malpractice (physician professional liability) insurance cost in the U.S.: what drives premiums by specialty and state, claims-made vs occurrence policies, tail and nose coverage when you switch or retire, consent-to-settle clauses, per-claim vs aggregate limits, and concrete ways to lower what you pay without leaving yourself exposed.
Daewon Pharmaceutical (KOSPI 003220) 2026 analysis: the Pelubi incrementally modified drug, Coldaewon squeeze-pouch cold medicine, hypertension and diabetes combination drugs, health-supplement expansion, versus drug-price cuts, generic competition, and R&D cost pressure.
LH (Labcorp) 2026 stock outlook. A qualitative deep dive into the clinical-lab duopoly with Quest, the economies-of-scale moat, hospital outreach lab acquisitions as a growth engine, diagnostic volume and reimbursement dynamics, residual CRO exposure after the Fortrea spin-off, dividends, and valuation.
Cardinal Health (CAH) 2026 stock outlook. A qualitative deep dive into the Big-3 drug-distribution oligopoly moat, razor-thin toll-road margins, generics sourcing scale, GLP-1 and specialty volume tailwinds, the GMPD turnaround, and the multi-year opioid-settlement tail.
Viatris (VTRS) 2026 stock outlook. A qualitative deep dive into the Pfizer Upjohn-Mylan merger, the debt paydown and dividend story, brand-revenue decline offset by complex generics and biosimilars, EpiPen's fading pricing power, and the key risks.